Publication | Closed Access

First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies

Malignant DiseaseMedicineInhibitor Bay 1238097PathologyExtra-terminal MotifAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer ResearchEscalation Study